Copyright
©The Author(s) 2023.
World J Gastrointest Surg. Nov 27, 2023; 15(11): 2398-2405
Published online Nov 27, 2023. doi: 10.4240/wjgs.v15.i11.2398
Published online Nov 27, 2023. doi: 10.4240/wjgs.v15.i11.2398
Treatment | Target | Limited |
Bile acid sequestrant trial | Bile acids secreted into the intestine are bound to reduce damage to intestinal tissues | Poorly tolerated due to stomach pain, bloating, flatulence, nausea and vomiting |
Bile acid receptor agonists | Receptor agonists reduce bile acid synthesis to relieve symptoms of diarrhoea | Potent FXR agonists may have adverse side effects |
Glucagon-like peptide 1 receptor agonist | Slows upper gastrointestinal motility and increases small intestine transit time | Further clinical trials and follow-up required |
Intestinal microbiota | Increased bile acid binding, excretion in faeces, and hepatic synthesis via an FGF-dependent mechanism after probiotic administration | Not intended to target the entire intestinal microbial community as a therapeutic approach |
Ursodeoxycholic acid | Reduces mucosal cytokine levels, inhibiting release of antimicrobial peptides and preventing apoptosis. | LCA metabolism may be required to allow full pharmacological effects of ursodeoxycholic acid |
Anti-diarrhoeal agents | Inhibit intestinal secretion and peristalsis, slowing intestinal transit and allowing increased fluid reabsorption to alleviate diarrheal symptoms | High doses or abuse may cause cardiotoxicity |
Dietary therapy | Vegetable dietary fiber prevents gastrointestinal diarrhea by reducing gastric emptying | May respond to a reduction of dietary cholesterol and fats |
- Citation: Huang RL, Huang WK, Xiao XY, Ma LF, Gu HZR, Yang GP. Diagnosis and treatment of post-cholecystectomy diarrhoea. World J Gastrointest Surg 2023; 15(11): 2398-2405
- URL: https://www.wjgnet.com/1948-9366/full/v15/i11/2398.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v15.i11.2398